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Background: The goal of this study was to investigate the expression of sarcosine metabolism-related proteins,
namely glycine N-methyltransferase (GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic acid oxidase (PIPOX),
in the different breast cancer subtypes and to assess the implications of differences in expression pattern according
to subtype.
Methods: We analyzed the expression of GNMT, SARDH, and PIPOX in a tissue microarray of 721 breast cancer
cases using immunohistochemistry (IHC). We classified breast cancer cases into subtype luminal A, luminal B, HER-2,
and triple negative breast cancer (TNBC) according to the status for the estrogen receptor (ER), progesterone
receptor (PR), HER-2, and Ki-67. Sarcosine metabolism phenotype was stratified according to IHC results for GNMT,
SARDH, and PIPOX: GNMT(+), SARDH and PIPOX(−) was classified as high sarcosine type; GNMT(−), SARDH or
PIPOX(−) as low sarcosine type; GNMT(+), SARDH or PIPOX(+) as intermediate sarcosine type, and GNMT(−), SARDH
and PIPOX(−) as null type.
Results: Expression of sarcosine metabolism-related proteins differed significantly according to breast cancer
subtype (GNMT, p = 0.005; SARDH, p = 0.012; tumoral PIPOX, p = 0.008; stromal PIPOX, p < 0.001). These proteins
were the most frequently expressed in HER-2 type tumors and the least in TNBC. Sarcosine metabolism phenotype
also varied according to breast cancer subtype, with high sarcosine type the most common in HER-2, and null type
the most common in TNBC (p = 0.003). Univariate analysis revealed that GNMT expression (p = 0.042), tumoral PIPOX
negativity (p = 0.039), and high sarcosine type (p = 0.021) were associated with shorter disease-free survival (DFS).
Multivariate analysis also revealed GNMT expression was an independent factor for shorter DFS (hazard ratio: 2.408,
95% CI: 1.154-5.024, p = 0.019).
Conclusion: Expressions of sarcosine metabolism-related proteins varied according to subtype of breast cancer,
with HER-2 type tumors showing elevated expression of these proteins, and TNBC subtype showing decreased
expression of these proteins. Expression of sarcosine metabolism-related proteins was also associated with breast
cancer prognosis.
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Sarcosine (N-methylglycine), a non-proteogenic amino acid
produced in the synthesis and degradation of glycine, is
produced by methyl group transfer from S-adenosylmethio-
nine (SAM) to glycine by glycine N-methyltransferase
(GNMT). Other major sarcosine-metabolizing enzymes -
sarcosine dehydrogenase (SARDH) and I-pipecloioc acid
oxidase (PIPOX) - detach the methyl group from sarcosine
via oxidative demethylation to form glycine [1]. The role of
sarcosine extends beyond its identity as a non-proteogenic
amino acid; it is also a potential oncometabolite. Prostate
cancer studies have reported that sarcosine is a sensitive
tumor biomarker and suggest its involvement in tumor
progression and metastatic processes [2-4].
Breast cancer is clinically, histopathologically, and
molecularly heterogeneous. Efforts to classify tumors
with similar characteristics have resulted in subtyping
of breast cancer into luminal A, luminal B, HER-2, nor-
mal breast-like, and basal-like types through genetic
profiling analysis [5,6]. A separate set of subtyping cri-
teria relies on the expression of important therapeutic
markers: estrogen receptor (ER), progesterone receptor
(PR), and HER-2, from which the term triple negative
breast cancer (TNBC) is derived. TNBC is defined as
breast cancer negative for all three markers, and a sig-
nificant overlap of biological and clinical characteristics
between TNBC and basal-like breast cancers, resulting
in more than 85% of TNBC belong to basal-like breast
cancer [7]. These molecular differences are associated
with histopathological and clinical differences as well as
variations in treatment response and prognosis, implicat-
ing possible differences in metabolic features. Previous
studies indicate elevated expression of the glycolysis-
related proteins GLUT-1 and CAIX in basal-like type/
TNBC breast cancers [8,9] and elevated expression of
the glutaminolysis-related protein in HER-2 type breast
cancers [10], supporting a plausible relation between
metabolism and molecular subtype. However, the asso-
ciation between breast cancer subtype and sarcosine
metabolism-related protein expression has not been ex-
amined. While most research on sarcosine up to date
has been done in prostate cancer, there exists consider-
able similarity and connection between prostate cancer
and breast cancer. Firstly, epidemiologic studies show
that family history of breast cancer significantly influences
the risk for prostate cancer [11,12]. Secondly, genetic stud-
ies showed that androgen receptor(AR) alteration, which
is important in the development of prostate cancer, is also
present in breast cancer [13]. Moreover, studies have
shown that the mutations significant for hereditary breast
cancer, BRCA1 and BRCA2 mutations, is related to higher
risk for prostate cancer [14,15]. Lastly, in a biochemical
aspect, the prostate cancer-sensitive marker PSA was also
detected in breast cancer [16], and its relation to goodprognosis of prostate cancer was reported [17]. Conclu-
sively, the epidemiologic, genetic and biochemical simi-
larities suggest a resemblance in sarcosine metabolism
between prostate cancer and breast cancer.
Therefore, in this study, we determined the expression
of sarcosine metabolism-related protein in various breast
cancer subtypes and investigated the implications of dif-
ferences in expression pattern according to subtype.Materials and methods
Patient selection
Subjects were selected from among patients diagnosed
with invasive breast cancer who received surgical treat-
ment from January 2000 to December 2006 at Severance
Hospital. Patients who received pre-operative hormone
or chemotherapy were excluded. This study was approved
by the Institutional Review Board of Yonsei University
Severance Hospital. IRB exempted the informed consent
from patients. All cases were reviewed retrospectively
by a breast pathologist (Koo JS) using Hematoxylin &
Eosin (H&E)-stained slides. Histological grade was assessed
using the Nottingham grading system [18]. Clinicopatho-
logic parameters evaluated in each case included patient
age at initial diagnosis, lymph node metastasis, tumor re-
currence, distant metastasis, and patient survival.Tissue microarray
A representative area was selected on an H&E-stained
slide, and a corresponding spot was marked on the surface
of the paraffin block. Using a biopsy needle, the selected
area was punched out, and a 3-mm tissue core was trans-
ferred to a 6 × 5 recipient block. Two tissue cores of inva-
sive tumor were extracted to minimize extraction bias.
Each tissue core was assigned a unique tissue microarray
location number that was linked to a database containing
other clinicopathologic data.Immunohistochemistry
Antibodies used for immunohistochemistry are listed in
Additional file 1: Table S1. All immunohistochemistry
was performed with formalin-fixed, paraffin-embedded
tissue sections. Briefly, 5-μm-thick sections were obtained
with a microtome, transferred onto adhesive slides, and
dried at 62°C for 30 minutes. After incubation with pri-
mary antibodies, immunodetection was performed with
biotinylated anti-mouse immunoglobulin, followed by
peroxidase-labeled streptavidin using a labeled streptavidin
biotin kit with 3,3′-diaminobenzidine chromogen as the
substrate. The primary antibody incubation step was omit-
ted in the negative control. Positive control tissue was
used as per the manufacturer’s recommendation. Slides
were counterstained with Harris hematoxylin.
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All immunohistochemical markers were accessed by
light microscopy. A cut-off value of 1% or more posi-
tively stained nuclei was used to define ER and PR posi-
tivity [19]. HER-2 staining was analyzed according to the
American Society of Clinical Oncology (ASCO)/College
of American Pathologists (CAP) guidelines using the fol-
lowing categories: 0 = no immunostaining; 1+ = weak in-
complete membranous staining, less than 10% of tumor
cells; 2+ = complete membranous staining, either uniform
or weak in at least 10% of tumor cells; and 3+ = uniform
intense membranous staining in at least 30% of tumor
cells [20]. HER-2 immunostaining was considered positive
when strong (3+) membranous staining was observed,
whereas cases with 0 to 1+ were regarded as negative.
Cases showing 2+ HER-2 expression were evaluated forTable 1 Clinicopathologic characteristics of patients accordin
Parameter Total
(n =721) (%)
Lum
(n =
Age (years)
≤50 428 (59.4) 173
>50 293 (40.6) 130
Histologic grade
I/II 485 (67.3) 275
III 236 (32.7) 28 (
Tumor stage
T1 355 (49.2) 169
T2/T3 366 (50.8) 134
Nodal metastasis
Absent 427 (59.2) 173
Present 294 (40.8) 130
Estrogen receptor status
Negative 259 (35.9) 5 (1
Positive 462 (64.1) 298
Progesterone receptor status
Negative 347 (48.1) 50 (
Positive 374 (51.9) 253
HER-2 status
Negative 565 (78.4) 303
Positive 156 (21.6) 0 (0
Ki-67 LI (%)
≤14 409 (56.7) 303
>14 312 (43.3) 0 (0
Tumor recurrence 63 (8.7) 15 (
No. of patient deaths 61 (8.5) 13 (
Duration of clinical follow-up (months, mean ± SD) 69.9 ± 31.2 71.9
Bold number represents p<0.05.
TNBC, triple negative breast cancer.HER-2 amplification by fluorescent in situ hybridization
(FISH).
Immunohistochemical markers for GNMT, SARDH,
and PIPOX were accessed by light microscopy. Immu-
nohistochemical staining was calculated as the product
of the proportion of stained cells and immunostaining
intensity. Proportion of stained cells was stratified as 0:
negative, 1: less than 30% positive, and 2: equal to or
more than 30% positive, while immunostaining intensity
was stratified as 0: negative, 1: weak, 2: moderate, and 3:
strong. Immunohistochemistry was deemed negative
when the product of the proportion of stained cells and
immunostaining intensity was 0–1 and positive when
the product was 2–6 [21]. Ki-67 labeling index (LI) was
defined as the percentage of cancer cells with a Ki-67-
positive nucleus.g to breast cancer phenotype
inal A
303) (%)
Luminal B
(n =169) (%)
HER-2
(n =71) (%)
TNBC
(n =178) (%)
P-value
0.012
(57.1) 113 (66.9) 32 (45.1) 110 (61.8)
(42.9) 56 (33.1) 39 (54.9) 68 (38.2)
<0.001
(90.8) 112 (66.3) 37 (52.1) 61 (34.3)
9.2) 57 (33.7) 34 (47.9) 117 (65.7)
0.002
(55.8) 86 (50.9) 32 (45.1) 68 (38.2)
(44.2) 83 (49.1) 39 (54.9) 110 (61.8)
0.162
(57.1) 93 (55.0) 44 (62.0) 117 (65.7)
(42.9) 76 (45.0) 27 (38.0) 61 (34.3)
<0.001
.7) 5 (3.0) 71 (100.0) 178 (100.0)
(98.3) 164 (97.0) 0 (0.0) 0 (0.0)
<0.001
16.5) 48 (28.4) 71 (100.0) 178 (100.0)
(83.5) 121 (71.6) 0 (0.0) 0 (0.0)
<0.001
(100.0) 84 (49.5) 0 (0.0) 178 (100.0)
.0) 85 (50.3) 71 (100.0) 0 (0.0)
<0.001
(100.0) 49 (29.0) 29 (40.8) 28 (15.7)
.0) 120 (71.0) 42 (59.2) 150 (84.3)
5.0) 13 (7.7) 11 (15.5) 24 (13.5) 0.002
4.3) 13 (7.7) 11 (15.5) 24 (13.5) 0.001
± 29.0 70.0 ± 30.1 66.1 ± 34.9 68.1 ± 34.1 0.419
Table 2 Expression of metabolism-related proteins according to breast cancer subtype
Parameter Total (n =721) (%) Luminal A (n =303) (%) Luminal B (n =169) (%) HER-2 (n =71) (%) TNBC (n =178) (%) P-value
GNMT 0.005
Negative 664 (92.1) 273 (90.1) 153 (90.5) 63 (88.7) 175 (98.3)
Positive 57 (7.9) 30 (9.9) 16 (9.5) 8 (11.3) 3 (1.7)
SARDH 0.012
Negative 597 (82.8) 261 (86.1) 130 (76.9) 53 (74.6) 153 (86.0)
Positive 124 (17.2) 42 (13.9) 39 (23.1) 18 (25.4) 25 (14.0)
PIPOX (T) 0.008
Negative 570 (79.1) 225 (74.3) 143 (84.6) 52 (73.2) 150 (84.3)
Positive 151 (20.9) 78 (25.7) 26 (15.4) 19 (26.8) 28 (15.7)
PIPOX (S) <0.001
Negative 671 (93.1) 287 (94.7) 154 (91.1) 58 (81.7) 172 (96.6)
Positive 50 (6.9) 16 (5.3) 15 (8.9) 13 (18.3) 6 (3.4)
Bold number represents p<0.05.
TNBC, triple negative breast cancer.
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Before FISH analysis, invasive tumors were examined on
hematoxylin-eosin stained slides. FISH was subsequently
performed on the tested tumor using a PathVysion HER-2
DNA Probe Kit (Vysis, Downers Grove, IL, USA) in ac-
cordance with the manufacturer’s instructions. HER-2
gene copy number was evaluated using an epifluores-
cence microscope (Olympus, Tokyo, Japan). At least 60
tumor cell nuclei in three separate regions were inves-
tigated for HER-2 and chromosome 17 signals. HER-2
gene amplification was determined according to the
ASCO/CAP guidelines [20]. An absolute HER-2 geneFigure 1 Expression of sarcosine metabolism-related proteins accordicopy number less than 4 or a HER-2 gene/chromosome
17 copy number ratio (HER-2/Chr17 ratio) less than
1.8 was considered HER-2 negative. An absolute HER-2
copy number between 4 and 6 or a HER-2/Chr17 ratio
between 1.8 and 2.2 was considered HER-2 equivocal.
An absolute HER-2 copy number greater than 6 or a
HER-2/Chr17 ratio higher than 2.2 was considered
HER-2 positive.
Tumor phenotype classification
In this study, we classified breast cancer phenotypes
according to the immunohistochemistry results for ER,ng to the molecular subtype of breast cancer.
Figure 2 A heatmap of the expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer.
T, tumor, S, stroma, red: positive, green: negative.
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follows [22]: luminal A type, ER or/and PR positive,
HER-2 negative and Ki-67 LI <14%; Luminal B type,
(HER-2 negative) ER or/and PR positive, HER-2 nega-
tive and Ki-67 LI ≥14%; (HER-2 positive) ER or/and PR
positive and HER-2 overexpressed or/and amplified;
HER-2 overexpression type, ER and PR negative and
HER-2 overexpressed or/and amplified; TNBC type:
ER, PR, and HER-2 negative.Sarcosine metabolism phenotype
Sarcosine metabolism phenotype was classified according
to immunohistochemistry results for GNMT, SARDH,
and PIPOX. High sarcosine type was defined as GNMT
(+)/SARDH and PIPOX(−), low sarcosine type was de-
fined as GNMT(−)/SARDH or PIPOX(+), intermedi-
ate sarcosine type was defined as GNMT(+)/SARDH
or PIPOX(+), and null type was defined as GNMT
(−)/SARDH and PIPOX(−).Statistical analysis
Data were analyzed using SPSS for Windows, Version
12.0 (SPSS Inc., Chicago, IL, USA). For determination of
statistical significance, Student’s t and Fisher’s exact tests
were used for continuous and categorical variables, re-
spectively. In the case of analyzing data with multiple
comparisons, a corrected p-value with the application of
the Bonferroni multiple comparison procedure was used.
Statistical significance was set to p < 0.05. Kaplan-Meier
survival curves and log-rank statistics were employed to
evaluate time to tumor recurrence and overall survival.
Multivariate regression analysis was performed using the
Cox proportional hazards model.Table 3 Sarcosine metabolism phenotypes of different breast
Parameter Total
(N =721) (%)
Luminal A
(n =303) (%)
Sarcosine metabolic type
High sarcosine type 36 (5.0) 16 (5.3)
Intermediate sarcosine type 21 (2.9) 14 (4.6)
Low sarcosine type 219 (30.4) 93 (30.7)
Null type 445 (61.7) 180 (59.4)
Bold number represents p<0.05.
TNBC, triple negative breast cancer.Results
Patient clinicopathologic characteristics
Of a total of 721 subjects, there were 303 (42.0%) luminal
A, 169 (23.4%) luminal B, 71 (9.8%) HER-2 type, and 178
(24.7%) TNBC. Clinicopathologic analysis revealed that
TNBC tumors had a higher histological grade (p < 0.001),
higher T stage (p = 0.002), and higher Ki-67 LI (p < 0.001)
than the other tumor sub-types. In contrast, the HER-2
type was associated with older patient age (p = 0.012),
higher tumor recurrence rate (p = 0.002), and higher
mortality (p = 0.001) than the other subtypes (Table 1).
Expression of sarcosine metabolism-related proteins
according to tumor phenotype
Analysis of sarcosine metabolism-related protein expres-
sion revealed differences in expression depending on mo-
lecular subtype. HER-2 type tumors the most frequently
showed the expression of GNMT (p = 0.005), SARDH
(p = 0.012), tumoral PIPOX (p = 0.008), and stromal
PIPOX (p < 0.001), while TNBC tumors the least fre-
quently exhibited the expression of all four proteins
(Table 2, Figure 1, and Figure 2). Sarcosine metabolism
phenotypes also varied according to molecular subtype;
HER-2 type tumors had the highest ratio of high sarcosine
type, while TNBC tumors had the highest ratio of null
type (p = 0.003, Table 3). Clinically, there were statistically
significant differences in ER expression (p = 0.049), PR ex-
pression (p = 0.011), Ki-67 LI (p = 0.007), and tumor recur-
rence (p = 0.022) according to sarcosine metabolism type.
Intermediate sarcosine type had the highest rate of ER and
PR positivity with a low Ki-67 LI, while null type tumors
had the lowest ER and PR positivity with a high Ki-67 LI.
High sarcosine type showed the highest tumor recurrence
rate (Table 4).cancer subtypes
Luminal B
(n =169) (%)
HER-2
(n =71) (%)
TNBC
(n =178) (%)
P-value
0.003
12 (7.1) 7 (9.9) 1 (0.6)
4 (2.4) 1 (1.4) 2 (1.1)
54 (32.0) 26 (36.6) 46 (25.8)
99 (58.6) 37 (52.1) 129 (72.5)
Table 4 Clinicopathologic characteristics of patients according to sarcosine metabolism type
Parameter Total
N =721 (%)
High sarcosine type
n = 36 (%)
Intermediate sarcosine type
n = 21 (%)
Low sarcosine type
n = 219 (%)
Null type
n = 445 (%)
P-value
Age (years) 0.200
≤50 428 (59.4) 26 (72.2) 13 (61.9) 120 (54.8) 269 (60.4)
>50 293 (40.6) 10 (27.8) 8 (38.1) 99 (45.2) 176 (39.6)
Histologic grade 0.351
I/II 485 (67.3) 29 (80.6) 13 (61.9) 147 (67.1) 296 (66.5)
III 236 (32.7) 7 (19.4) 8 (38.1) 72 (32.9) 149 (33.5)
Tumor stage 0.082
T1 355 (49.2) 12 (33.3) 10 (47.6) 120 (54.8) 213 (47.9)
T2/T3 366 (50.8) 24 (66.7) 11 (52.4) 99 (45.2) 232 (52.1)
Nodal metastasis 0.799
Absent 427 (59.2) 22 (61.1) 14 (66.7) 125 (57.1) 266 (59.8)
Present 294 (40.8) 14 (38.9) 7 (33.3) 94 (42.9) 179 (40.2)
Estrogen receptor status 0.049
Negative 259 (35.9) 9 (25.0) 3 (14.3) 75 (34.2) 172 (38.7)
Positive 462 (64.1) 27 (75.0) 18 (85.7) 144 (65.8) 273 (61.3)
Progesterone receptor status 0.011
Negative 347 (48.1) 13 (36.1) 4 (19.0) 102 (46.6) 228 (51.2)
Positive 374 (51.9) 23 (63.9) 17 (81.0) 117 (53.4) 217 (48.8)
HER-2 status 0.072
Negative 565 (78.4) 24 (66.7) 17 (81.0) 163 (74.4) 361 (81.1)
Positive 156 (21.6) 12 (33.3) 4 (19.0) 56 (25.6) 84 (18.9)
Ki-67 LI (%) 0.007
≤14 409 (56.7) 21 (58.3) 17 (81.0) 138 (63.0) 233 (52.4)
>14 312 (43.3) 15 (41.7) 4 (19.0) 81 (37.0) 212 (47.6)
Tumor recurrence 63 (8.7) 8 (22.2) 1 (4.8) 15 (6.8) 39 (8.8) 0.022
No. of patient deaths 61 (8.5) 5 (13.9) 1 (4.8) 20 (9.1) 35 (7.9) 0.558
Bold number represents p<0.05.
TNBC, triple negative breast cancer.
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metabolism-related proteins and clinicopathologic factors
Analysis of sarcosine metabolism-related protein expression
and clinicopathologic parameters showed an association be-
tween PR positivity and GNMT expression (p = 0.016), be-
tween HER-2 positivity and SARDH expression (p = 0.016)
and stromal PIPOX expression (p = 0.004). Moreover,
tumoral PIPOX expression was associated with lower
Ki-67 LI (p < 0.001, Table 5).
Impact of expression of sarcosine metabolism-related
proteins on patient prognosis
To investigate the potential effects of sarcosine metabolism-
related protein expression on prognosis, univariate analysis
was performed on all cases regardless of subtype. Factors
associated with shorter disease-free survival (DFS) were
GNMT expression (p = 0.042), tumoral PIPOX negativity
(p = 0.039), and high sarcosine type (p = 0.021, Table 6 andFigure 3). Multivariate Cox analysis revealed that higher T
stage (hazard ratio: 2.123, 95% CI: 1.167-3.861, p = 0.014),
lymph node metastasis (hazard ratio: 2.344, 95% CI: 1.389-
3.956, p = 0.001), and GNMT expression (hazard ratio:
2.408, 95% CI: 1.154-5.024, p = 0.019) were independent
factors associated with shorter DFS. Additionally, higher T
stage (hazard ratio: 1.829, 95% CI: 1.028-3.255, p = 0.040)
and lymph node metastasis (hazard ratio: 1.971, 95% CI:
1.166-3.333, p = 0.011) were independent factors associ-
ated with shorter overall survival (OS) (Table 7).
The effect of sarcosine metabolism-related protein
expression on prognosis according to molecular subtype
was studied. In luminal A, univariate analysis showed
that SARDH expression was associated with shorter OS
(p = 0.010, Figure 4), and SARDH expression was an in-
dependent factor for shorter OS (hazard ratio: 3.793,
95% CI: 1.231-11.68, p = 0.020). In luminal B, GNMT
expression (p = 0.003 and 0.020, respectively) and high
Table 5 Correlations between the expression of sarcosine metabolism-related proteins and clinicopathologic
parameters
Parameter GNMT SARDH PIPOX in tumor PIPOX in stroma
Negative
n =664
(%)
Positive
n = 57
(%)
P-value* Negative
n =597
(%)
Positive
n = 124
(%)
P-value* Negative
n = 570
(%)
Positive
n = 151
(%)
P-value* Negative
n = 671
(%)
Positive
n =50
(%)
P-value*
Age (years) 0.588 0.336 0.620 1.088
≤50 389 (58.6) 39 (68.4) 363 (60.8) 65 (52.4) 346 (60.7) 82 (54.3) 402 (59.9) 26 (52.0)
>50 275 (41.4) 18 (31.6) 234 (39.2) 59 (47.6) 224 (39.3) 69 (45.7) 269 (40.1) 24 (48.0)
Histologic
grade
1.128 3.068 3.036 1.024
I/II 443 (66.7) 42 (73.7) 403 (67.5) 82 (66.1) 385 (67.5) 100 (66.2) 455 (67.8) 30 (60.0)
III 221 (33.3) 15 (26.3) 194 (32.5) 42 (33.9) 185 (32.5) 51 (33.8) 216 (32.2) 20 (40.0)
Tumor stage 0.376 1.316 0.308 3.644
T1 333 (50.2) 22 (38.6) 289 (48.4) 66 (53.2) 271 (47.5) 84 (55.6) 330 (49.2) 25 (50.0)
T2/T3 331 (49.8) 35 (61.4) 308 (51.6) 58 (46.8) 299 (52.5) 67 (44.4) 341 (50.8) 25 (50.0)
Nodal
metastasis
2.116 3.640 2.604 2.524
Absent 391 (58.9) 36 (63.2) 353 (59.1) 74 (59.7) 340 (59.6) 87 (57.6) 399 (59.5) 28 (56.0)
Present 273 (41.1) 21 (36.8) 244 (40.9) 50 (40.3) 230 (40.4) 64 (42.4) 272 (40.5) 22 (44.0)
Estrogen
receptor status
0.060 3.644 1.672 2.132
Negative 247 (37.2) 12 (21.1) 215 (36.0) 44 (35.5) 209 (36.7) 50 (33.1) 239 (35.6) 20 (40.0)
Positive 417 (62.8) 45 (78.9) 382 (64.0) 80 (64.5) 361 (63.3) 101 (66.9) 432 (64.4) 30 (60.0)
Progesterone
eceptor status
0.004 1.572 0.204 3.020
Negative 330 (49.7) 17 (29.8) 283 (47.4) 64 (51.6) 285 (50.0) 62 (41.1) 324 (48.3) 23 (46.0)
Positive 334 (50.3) 40 (70.2) 314 (52.6) 60 (48.4) 285 (50.0) 89 (58.9) 347 (51.7) 27 (54.0)
HER-2 status 0.876 0.004 3.072 0.001
Negative 524 (78.9) 41 (71.9) 480 (80.4) 85 (68.5) 448 (78.6) 117 (77.5) 535 (79.7) 30 (60.0)
Positive 140 (21.1) 16 (28.1) 117 (19.6) 39 (31.5) 122 (21.4) 34 (22.5) 136 (20.3) 20 (40.0)
Ki-67 LI (%) 0.456 3.156 <0.001 1.280
≤14 371 (55.9) 38 (66.7) 340 (57.0) 69 (55.6) 303 (53.2) 106 (70.2) 384 (57.2) 25 (50.0)
>14 293 (44.1) 19 (33.3) 257 (43.0) 55 (44.4) 267 (46.8) 45 (29.8) 287 (42.8) 25 (50.0)
Bold number represents p<0.05.
*p-value was calculated by Bonferroni method.
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related with both shorter DFS and shorter OS (Figure 5),
but no correlation was found in multivariate Cox ana-
lysis (Additional file 1: Table S2 and Additional file 1:
Table S3).
Discussion
We investigated the expression of sarcosine metabolism-
related proteins in breast cancer, with a focus on mo-
lecular subtypes of breast cancer. GNMT, SARDH, and
PIPOX showed the highest expression levels in HER-2
type cancer. Sarcosine has mostly been researched in pros-
tate cancer; studies have shown that increased sarcosine
level is associated with cancer progression, and in vitro
and in vivo models have suggested a correlation betweenprostate cancer growth and progression [2]. Key results
include the induction of invasive phenotypes by injec-
tion of sarcosine into benign prostate cells [1] and in-
creased sarcosine levels in prostate cancer tissue [23].
Increased sarcosine levels in prostate cancer can be use-
ful in cancer detection. Reports revealed that sarcosine
had higher predictive value in detecting prostate cancer
in tissue biopsy than PSA, particularly when PSA level
was between 2 to 10 ng/ml or the gray zone [1], or when
it was less than 4 ng/ml [24,25]. Moreover, sarcosine
levels and GNMT expression were also increased in tis-
sue and feces of experimental azoxymethane-induced
colorectal cancer [26].
Unfortunately, there is no prior research on sarcosine
in breast cancers against which to compare our study
Table 6 Univariate analysis of the impact of expression of serine/glycine metabolism-related proteins in breast cancers
on disease-free survival and overall survival by the log-rank test
Parameter Number of patients/
recurrence/death
Disease-free survival Overall survival
Mean survival (95% CI) months P -value Mean survival (95% CI) months P -value
GNMT 0.042 0.498
Negative 664/54/55 127 (123–130) 129 (127–132)
Positive 57/9/6 98 (91–106) 126 (116–135)
SARDH 0.767 0.264
Negative 597/53/47 126 (122–130) 130 (127–133)
Positive 124/10/14 121 (115–127) 124 (117–132)
PIPOX (T) 0.039 0.361
Negative 570/57/52 126 (123–129) 129 (126–131)
Positive 151/6/9 123 (117–129) 131 (126–135)
PIPOX (S) 0.927 0.636
Negative 671/59/58 126 (122–130) 129 (126–132)
Positive 50/4/3 122 (114–130) 126 (119–132)
Sarcosine metabolic type 0.021 0.503
High sarcosine type 36/8/5 90 (79–101) 118 (106–130)
Intermediate sarcosine type 21/1/1 108 (102–114) 132 (122–143)
Low sarcosine type 219/15/20 120 (115–125) 126 (121–132)
Null type 445/39/35 127 (124–131) 130 (127–133)
Bold number represents p<0.05.
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sarcosine metabolism-related proteins and prostate can-
cer. Compared to normal prostate tissue, prostate cancer
tissue showed higher expression of GNMT, the sarcosine
generating enzyme, and lower expression of SARDH and
PIPOX, which are sarcosine metabolizing enzymes, sug-
gesting a correlation between sarcosine level and the ex-
pression of sarcosine metabolism-related proteins [2].
Although we did not measure sarcosine levels directly
from breast cancer tissues, we used expression levels ofFigure 3 Disease-free survival and overall survival according to the e
metabolism phenotype.the major sarcosine metabolism-related proteins GNMT,
SARDH, and PIPOX as surrogate for sarcosine level.
The expression rate of GNMT, SARDH, and PIPOX were
higher in HER-2 type relative to the others subtypes.
Moreover, the proportion of high sarcosine type [GNMT
(+)/SARDH and PIPOX(−)] was highest in HER-2 type tu-
mors, suggesting that sarcosine levels are higher in HER-2
type breast cancers than in other molecular subtypes.
The mechanism underlying higher expression of sarco-
sine metabolism-related protein in HER-2 type tumorsxpression of sarcosine metabolism-related proteins and sarcosine
Table 7 Multivariate analysis of breast-cancer survival
Included parameters Disease-free survival Overall survival
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
T stage 0.014 0.040
T1 versus T2-3 2.123 1.167-3.861 1.829 1.028-3.255
N stage 0.001 0.011
N0 versus N1-3 2.344 1.389-3.956 1.971 1.166-3.333
Histologic grade 0.632 0.545
I/II versus III 1.143 0.661-1.977 0.839 0.475-1.482
ER status 0.111 0.079
Negative versus Positive 1.795 0.874-3.686 1.888 0.929-3.836
PR status 0.198 0.070
Negative versus Positive 1.638 0.773-3.473 2.036 0.944-4.393
HER-2 status 0.469 0.508
Negative versus Positive 1.235 0.697-2.188 1.214 0.683-2.159
GNMT 0.019 0.272
Negative versus Positive 2.408 1.154-5.024 1.622 0.684-3.849
PIPOX (T) 0.069 0.563
Negative versus Positive 0.457 0.196-1.064 0.810 0.397-1.652
Bold number represents p<0.05.
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hypothesis is that sarcosine, HER-2, and the androgen
receptor influence each other. A previous study showed
that sarcosine increased both HER-2 mRNA and protein
levels in an androgen-dependent prostate cancer cell line,
suggesting an association among the androgen receptor,
HER-2, and sarcosine [27]. Correspondingly, the molecu-
lar apocrine type in breast cancer defined as ER-negative
and AR-positive breast cancer showed significant overlapFigure 4 Overall survival according to the expression of SARDH
in luminal A type breast cancer.with the HER-2-enriched group on gene profiling analysis
[28]. Approximately 50% of molecular apocrine type
exhibited HER-2 amplification/overexpression, strongly
implying a correlation between AR and HER-2. Further
research on the effects of sarcosine on HER-2 accord-
ing to AR status will help elucidate the mechanism of
association among these key molecules in breast cancer.
Another interesting finding is the correlation between
GNMT positivity/PIPOX negativity and shorter DFS. A
previous prostate cancer study revealed that increased
levels of sarcosine induce invasion and intravasation [2],
supporting the role of sarcosine as an oncometabolite in
prostate cancer. A separate study showed that serum
sarcosine levels were significantly higher in patients with
metastatic prostate cancer [29]. It follows that sarcosine
levels would be higher in breast cancer with positive
GNMT and negative PIPOX, which could be the reason
for shorter DFS in such breast cancer. Moreover, ana-
lysis of sarcosine metabolism phenotype revealed that
patients with sarcosine-high type [GNMT(+)/SARDH
and PIPOX(−)] tumors had a shorter DFS than patients
with other breast cancer tumor types, suggesting that
sarcosine level is a prognostic factor in breast cancer. A
previous study reported a potential association between
high GNMT cytoplasmic expression in prostate cancer
and lower DFS rate [30], consistent with our findings.
In contrast, research on hepatic cholangiocarcinoma
suggests that GNMT expression was a favorable prog-
nostic marker [31]. It is highly likely that sarcosine may
have different roles according to the type and subtype of
Figure 5 Disease-free survival and overall survival according to the expression of GNMT and sarcosine metabolism phenotype in
luminal B type breast cancer.
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relation between sarcosine level and cancer prognosis
are necessary. That sarcosine metabolism-related pro-
teins expression was significantly lower in TNBC-type
tumors relative to the other subtypes was an unexpected
result. TNBC tumors have highly aggressive histological
characteristics such as high histologic grade, high levels
of mitosis and tumor necrosis [7]. Accordingly, we ex-
pected TNBC tumor specimens to exhibit strong meta-
bolic activity, as previous studies have reported increased
expression of Glut-1 and CAIX in TNBC compared to
other breast cancer subtypes [8,9]. Our results imply
that sarcosine does not contribute significantly to the
aggressiveness of TNBC. This topic requires further
investigation.Conclusion
The expressions of sarcosine metabolism-related pro-
teins varied according to subtype of breast cancer; ex-
pression of these proteins was elevated in HER-2 type
and decreased in TNBC. We also demonstrated that
sarcosine metabolism-related proteins had prognostic
utility in breast cancer patients.Additional file
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